statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the...

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR...

Abivax reports 2023 financial results and operational update

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics...

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET Abivax SA (Euronext Paris and Nasdaq: ABVX) ( Abivax or the Company ), a...

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December...

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024...

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in...

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

Abivax 2024 Financial Communication Calendar PARIS, France, January 4, 2024, 8:30 a.m. CET Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the Company ), a clinical-stage biotechnology...

Abivax 2024 Financial Communication Calendar

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Volume	21,547.00
52-Wk High	$17.02
52-Wk Low	$8.00

ABVX Abivax - ADR

About

Feed

News

Sentiment

Fundamentals